Karo Pharma AB Logo

Karo Pharma AB

Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.

KARO | ST

Overview

Corporate Details

ISIN(s):
NO0010308240 (+4 more)
LEI:
213800G54Z51LOPGTA79
Country:
Sweden
Address:
BOX 16184, 103 24 STOCKHOLM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Karo Healthcare (formerly Karo Pharma AB) is a healthcare company focused on providing 'smart choices for everyday healthcare.' The company develops, acquires, and commercializes a diverse portfolio of branded products, including over-the-counter (OTC) medicines, consumer health goods, and prescription pharmaceuticals, with a strategic emphasis on skin health. Its mission is to empower consumers to prevent illness and treat common health problems. Karo Healthcare's products are available in over 90 countries, with Europe and the Nordic region serving as its core markets. The company pursues growth through a consumer-centric, omnichannel strategy, combining organic innovation with strategic acquisitions to expand its brand portfolio and global presence.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-05-31 16:00
Post-Annual General Meeting Information
Kommuniké från Karo Pharmas årsstämma 2022
Swedish 1.4 MB
2022-05-27 16:00
Pre-Annual General Meeting Information
Ändringar i Karo Intressenter AB:s förslag avseende val av styrelse till Karo P…
Swedish 1.1 MB
2022-05-02 18:30
Pre-Annual General Meeting Information
KALLELSE TILL ÅRSSTÄMMA I KARO PHARMA AKTIEBOLAG
Swedish 4.9 MB
2022-04-19 08:30
Share Issue/Capital Change
Karo Pharmas företrädesemission fulltecknad
Swedish 3.6 MB
2022-04-19 08:30
Share Issue/Capital Change
Karo Pharma’s rights issue fully subscribed
English 3.6 MB
2022-04-01 13:30
M&A Activity
Karo Pharma slutför förvärvet av E45® från Reckitt
Swedish 21.3 KB
2022-04-01 13:30
M&A Activity
Karo Pharma completes the acquisition of the E45® brand from Reckitt
English 46.1 KB
2022-03-23 12:00
Delisting Announcement
Karo Pharma offentliggör prospekt avseende företrädesemissionen och erhåller go…
Swedish 460.3 KB
2022-03-23 12:00
Report Publication Announcement
Karo Pharma publishes prospectus relating to the rights issue and receives appr…
English 438.3 KB
2022-03-16 08:00
Share Issue/Capital Change
Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2.…
English 156.1 KB
2022-03-16 08:00
Share Issue/Capital Change
Karo Pharma beslutar om en fullt garanterad företrädesemission om cirka 2,5 mil…
Swedish 156.3 KB
2022-03-10 14:00
Delisting Announcement
Karo Pharma receives approval to delist the Company’s share from Nasdaq Stockho…
English 697.2 KB
2022-03-10 14:00
Delisting Announcement
Karo Pharma erhåller villkorat godkännande om avnotering av Bolagets aktier frå…
Swedish 696.0 KB
2022-03-09 12:00
Delisting Announcement
Karo Pharma applies for delisting of the Company’s shares from Nasdaq Stockholm…
English 51.0 KB
2022-03-09 12:00
Delisting Announcement
Karo Pharma ansöker om avnotering av Bolagets aktier från Nasdaq Stockholm i sa…
Swedish 51.7 KB

Automate Your Workflow. Get a real-time feed of all Karo Pharma AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Karo Pharma AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Karo Pharma AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America INBX
InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America INM
Inmune Bio, Inc. Logo
Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.
United States of America INMB
Innate Pharma SA Logo
Developing first-in-class antibody immunotherapies for cancer via the innate immune system.
United States of America IPHA
INOVIO PHARMACEUTICALS, INC. Logo
Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.
United States of America INO
Insight Molecular Diagnostics Inc. Logo
Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.
United States of America IMDX
INSMED Inc Logo
Develops and commercializes innovative therapies for serious and rare diseases.
United States of America INSM
Instil Bio, Inc. Logo
Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.
United States of America TIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.